Pfizer (NYSE: PFE) recently posted its Q1 results, which were below street estimates. The company's overall sales grew 1% while adjusted earnings grew 12%. While the Oncology segment did well, led by a ramp up in Ibrance sales, most of the other pharmaceuticals segments saw revenue declines....
Pfizer (NYSE: PFE) recently posted its Q1 results, which were below street estimates. The company's overall sales grew 1% while adjusted earnings grew 12%. While the Oncology segment did well, led by a ramp up in Ibrance sales, most of the other pharmaceuticals segments saw revenue declines....
Share this Article
Recommended